Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Front Immunol ; 11: 1865, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32983103

RESUMO

Neurally mediated syncope (NMS) is the most common underlying disease of pediatric syncope, which generally includes vasovagal syncope (VVS), postural tachycardia syndrome (POTS), and situational syncope. Allergic diseases involving the respiratory system, digestive system, skin, and other systems are prevalent in children. In recent years, increasing attention has been paid to children with the comorbidity of NMS and allergic diseases. This article reviews the featured clinical manifestations and pathogenesis of the comorbidity according to the progress of related studies. Clinical studies have shown that the comorbidity rate of pediatric VVS and/or POTS with allergic diseases amounts to ~30-40%, referring to the whole population of children with VVS and/or POTS. Additionally, children with the comorbidity present some relatively special clinical characteristics. A series of mechanisms or regulatory factors relating to allergies, such as the imbalance of vasoactive elements, dysfunction of the autonomic nervous system (ANS), and autoimmunity may play a role in the development of the comorbidity. Moreover, 90% of children with cough syncope, a type of situational syncope, have a history of asthma, indicating a potential relationship between asthma and NMS. Further studies exploring the clinical characteristics and pathogenesis of the comorbidity are still needed to aid in the diagnosis and treatment of children with NMS.


Assuntos
Hipersensibilidade/epidemiologia , Síncope/imunologia , Criança , Pré-Escolar , Comorbidade , Feminino , Humanos , Masculino
2.
Gynecol Oncol ; 159(3): 794-798, 2020 12.
Artigo em Inglês | MEDLINE | ID: mdl-32951892

RESUMO

OBJECTIVES: Current grading systems for platinum hypersensitivities (pHSR) rely on subjective features rather than objective clinical signs leading to inconsistencies in grading. To standardize classification of pHSR, a clinical grading system was developed at our institution. We report the clinical outcomes our classification system and evaluate its correlation with the classification systems currently published and used in practice. METHODS: This was a retrospective review of patients with pHSR from 2011 to 2017. Demographics, chemotherapeutic histories (CT), and details of their initial HSR were collected. Mild reactions were defined as local skin manifestations only. Moderate-low reactions included widespread skin, respiratory or GI findings. Moderate-standard reactions were defined as transient cardiovascular compromise (CVC), hypoxia or neurologic changes whereas sustained changes (>10 min) were used to define severe reaction. Fischer Exact Tests (p < .05) and binary logistic regression analyses were performed. Spearman correlation were used to assess relationships between our grading system and the NCCN and CTCAEv4.0 criteria. RESULTS: 87 patients were identified with most having ovarian cancer (n = 55, 63.2%), receiving carboplatin (n = 62, 71.3%), and on second-line CT (n = 34, 42.5%). Chest pain was associated with transient CVC (OR 10.0, 95% CI 1.148-87.133) while nausea/vomiting (OR 8.420, 95% CI 1.263-55.275) was associated with transient hypoxia albeit less closely than transient hypotension (OR 17.010, 95% CI 2.026-142.825). Only presyncope/syncope remained associated with sustained CVC (OR 38.0, 95% CI 2.815-512.912) on logistic regression. The classification system was most strongly correlated with the NCCN grading system (ρ 0.761, p < .001). CONCLUSIONS: This classification system offers an objective means of grading pHSR severity and correlates with currently-used grading systems.


Assuntos
Antineoplásicos/efeitos adversos , Hipersensibilidade a Drogas/diagnóstico , Neoplasias do Endométrio/tratamento farmacológico , Neoplasias Ovarianas/tratamento farmacológico , Índice de Gravidade de Doença , Adulto , Idoso , Idoso de 80 Anos ou mais , Carboplatina/efeitos adversos , Dor no Peito/epidemiologia , Dor no Peito/imunologia , Cisplatino/efeitos adversos , Hipersensibilidade a Drogas/complicações , Hipersensibilidade a Drogas/epidemiologia , Hipersensibilidade a Drogas/imunologia , Feminino , Humanos , Hipotensão/epidemiologia , Hipotensão/imunologia , Hipóxia/epidemiologia , Hipóxia/imunologia , Pessoa de Meia-Idade , Náusea/epidemiologia , Náusea/imunologia , Estudos Retrospectivos , Fatores de Risco , Síncope/epidemiologia , Síncope/imunologia , Vômito/epidemiologia , Vômito/imunologia
3.
BMJ Case Rep ; 20182018 Jun 04.
Artigo em Inglês | MEDLINE | ID: mdl-29866668

RESUMO

There are only six cases in literature that describe development of dystonia with Sjogren's syndrome (SS). We describe a case of a 43-year-old woman who presented with symptoms including movement disorder, sensory neurogenic bladder, sensory loss and neuropathic pain, migraine like headaches, musculoskeletal pain, Raynaud's phenomenon and dysautonomia. Symptoms started in 2000, with weakness that progressed to dystonia in 2003. Diagnostic work-up was inconclusive with negative inflammatory serologies, cerebrospinal fluid and MRI for many years. After patient developed sicca syndrome with dry eyes and mouth in 2009, her rheumatoid factor titre was elevated (550 IU/mL), erythrocyte sedimentation rate, anti-Sjogrens syndrome-related antigen A (anti-Ro/SSA) and anti-SSB/La: anti-Sjogrens syndrome-related antigen B (anti-La/SSB) became positive. Lip biopsy confirmed diagnosis of SS. She was diagnosed with primary SS with neurological involvement. Her symptoms responded well to intravenous methylprednisolone. Symptoms stabilised with trials of immune-suppressive therapy. This is a case that demonstrates the delay of diagnosing SS with preceding unique neurological association.


Assuntos
Distonia/diagnóstico , Síndrome de Sjogren/diagnóstico , Adulto , Anticorpos Antinucleares/imunologia , Distonia/etiologia , Distonia/imunologia , Feminino , Humanos , Imunossupressores/uso terapêutico , Transtornos de Enxaqueca/diagnóstico , Transtornos de Enxaqueca/etiologia , Transtornos de Enxaqueca/imunologia , Neuralgia/diagnóstico , Neuralgia/etiologia , Neuralgia/imunologia , Disautonomias Primárias/diagnóstico , Disautonomias Primárias/etiologia , Disautonomias Primárias/imunologia , Doença de Raynaud/diagnóstico , Doença de Raynaud/etiologia , Doença de Raynaud/imunologia , Glândulas Salivares Menores/patologia , Transtornos de Sensação/diagnóstico , Transtornos de Sensação/etiologia , Transtornos de Sensação/imunologia , Síndrome de Sjogren/complicações , Síndrome de Sjogren/tratamento farmacológico , Síndrome de Sjogren/imunologia , Síncope/diagnóstico , Síncope/etiologia , Síncope/imunologia , Bexiga Urinaria Neurogênica/diagnóstico , Bexiga Urinaria Neurogênica/etiologia , Bexiga Urinaria Neurogênica/imunologia
6.
Diabetes Res Clin Pract ; 49(1): 65-9, 2000 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-10808065

RESUMO

The type B insulin-resistance syndrome is characterized by the presence of anti-insulin receptor antibodies that cause severe insulin resistance. Treatments including steroids, cyclophosphamide, plasmapheresis, or insulin-like growth factor-1 (IGF-1) are chosen according to severity of insulin resistance. We describe a patient with type B insulin resistance syndrome who was treated successfully with human recombinant (hr) IGF-1, although this treatment provoked a severe allergic reaction. An elderly man with impaired glucose tolerance and unpredictable hypoglycemic episodes which were gradually worsening increased in hemoglobin (Hb)A1c concentration from 6.5 to 13.4%. His fasting and postprandial hyperglycemia were associated with severe hyperinsulinemia. The patient was diagnosed with type B insulin-resistance syndrome by the presence of anti-insulin receptor antibodies. Double-filtration plasmapheresis, plasma exchange, and immunosuppressive therapy with cyclophosphamide and cyclosporin all failed to suppress anti-insulin receptor antibodies more than transiently. When we attempted the treatment by daily administration of hrIGF-1, fasting and postprandial plasma glucose concentrations became normal and HbA1c levels decreased to 7.1% over 2 months, until on one occasion administration resulted in anaphylaxis. After the patient became stable, desensitization therapy was performed successfully, and hrIGF-1 could be administered again with the plasma glucose returning. We concluded that IGF-1 therapy was an effective treatment choice for type B insulin-resistance syndrome in cases whose plasma exchange and immunosuppressive therapy have failed.


Assuntos
Autoanticorpos/imunologia , Resistência à Insulina/imunologia , Fator de Crescimento Insulin-Like I/uso terapêutico , Receptor de Insulina/imunologia , Idoso , Glicemia/análise , Peptídeo C/sangue , Ciclofosfamida/uso terapêutico , Ciclosporina/uso terapêutico , Dessensibilização Imunológica , Teste de Tolerância a Glucose , Hemoglobinas Glicadas/análise , Humanos , Hiperglicemia/tratamento farmacológico , Imunossupressores/uso terapêutico , Fator de Crescimento Insulin-Like I/imunologia , Fator de Crescimento Insulin-Like I/normas , Masculino , Troca Plasmática , Plasmaferese , Síncope/imunologia
7.
Clin Chem Lab Med ; 38(1): 33-9, 2000 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-10774959

RESUMO

Two-site immunoassay methods have become the standard technique for measurement of a wide variety of drugs, hormones, and cell proteins. One limitation of these methods is their susceptibility to interference from heterophilic antibodies present in the sera of some patients. Human anti-murine antibodies represent a common heterophile antibody that can bind to mouse immunoglobulin and as well as to immunoglobulin from other species. While the mechanism of human anti-murine antibody interference has been well characterized, the time course over which this interference occurs and the susceptibility of different immunoassay procedures to human anti-murine antibody interference from patients with human anti-murine antibody have not been as well described. We report on the time course of interference in assays for cardiac markers for two patients with human anti-murine antibodies. We measured creatine kinase MB isoenzyme (CKMB) and troponins I and T using three different vendors' immunoassay procedures. Our results demonstrate that assay interference due to human anti-murine antibody interference is a transient phenomenon. In one of our patients, human anti-murine antibody interference appeared suddenly, peaked approximately 9 days following its appearance, and gradually resolved over the next 3 weeks. In addition, we found that immunoassay methods from different vendors can show highly variable interference effects when human anti-murine antibody-containing specimens are analyzed.


Assuntos
Anticorpos Heterófilos/imunologia , Biomarcadores/análise , Cardiopatias/diagnóstico , Técnicas Imunoenzimáticas/métodos , Idoso , Animais , Constrição Patológica/sangue , Constrição Patológica/enzimologia , Constrição Patológica/imunologia , Endarterectomia , Feminino , Cardiopatias/sangue , Cardiopatias/imunologia , Humanos , Masculino , Camundongos , Reprodutibilidade dos Testes , Síncope/sangue , Síncope/enzimologia , Síncope/imunologia , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...